Sen-Jam Pharmaceutical has announced the commencement of a Phase 2 clinical trial for SJP-001, a first-in-class therapeutic aimed at preventing alcohol hangovers. The trial, being conducted in Australia, marks a significant step toward addressing a widespread global health and productivity issue.
SJP-001 is a novel combination therapy supported by Sen-Jam's portfolio of 23 patents. It is designed to target the inflammatory response triggered by alcohol consumption, which is believed to be the primary cause of hangover symptoms. This approach differs from traditional remedies that focus on hydration or other less effective methods.
Innovative Funding Model
Sen-Jam has utilized a unique funding model that includes crowdfunding and the sale of Fractional Royalty Rights (FRR) on its patent portfolio. This approach has allowed the company to engage over 960 investors, with 24% reinvesting, demonstrating strong community support for SJP-001.
"Our FRR offering allows everyday people to directly support innovation while creating an opportunity for financial returns. It also enables us to return capital to our investors soon after licensing deals are in place," said Jim Iversen, CEO of Sen-Jam Pharmaceutical.
Pre-clinical Promise
Pre-clinical studies of SJP-001 have shown significant promise in reducing the severity and duration of hangover symptoms. "Our approach is grounded in cutting-edge international research that has identified inflammation as the primary driver of these alcohol related symptoms," said Jackie Iversen RPh MS, Co-Founder and Chief Clinical Officer at Sen-Jam Pharmaceutical.
The development of SJP-001 aligns with Sen-Jam's commitment to protecting cells and tissues from acute and chronic inflammatory responses. The company aims to promote health and maximize productivity by supporting individuals who choose to consume moderate amounts of alcohol.
Market Opportunity
With billions of adults worldwide consuming alcohol occasionally, the market potential for an effective hangover prevention therapy is substantial. The Center for Disease Control and Prevention (CDC) estimates that alcohol consumption costs the US $180 billion annually in lost productivity.
Sen-Jam Pharmaceutical is dedicated to developing innovative solutions for pain and inflammation, with a focus on repurposing small molecules and utilizing the 505(b)2 regulatory pathway.
